Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Neo Cremar Co. Ltd. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are assigned to 2 distinct examiners, ensuring that each matter is reviewed by a different individual. The prosecution is also spread across 2 distinct art units, indicating a variety of technical focuses within the pharmaceutical field.
LAU, JONATHAN S is the busiest examiner for the company, currently overseeing 1 pending office action. Since there are 2 distinct examiners for the 2 pending office actions, the workload is evenly divided. The 2 distinct art units involved suggest that the company's pharmaceutical innovations are being reviewed by different specialized groups at the patent office.
Practitioners should be prepared to navigate the requirements of 2 distinct examiners across 2 distinct art units. The lack of examiner overlap among the 2 pending office actions means that each case will likely be examined independently. LAU, JONATHAN S, as the busiest examiner with 1 pending office action, represents a portion of a prosecution effort involving 2 distinct examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LAU, JONATHAN S | 1 | 63.9% | -17.2% |
| SCHWECHTER, BRANDON ROSS | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18726900 | COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE COMPRISING GALACTO-OLIGOSACCHARIDE | LAU, JONATHAN S | — |
| 18712697 | NEW PEPTIDE AND USES THEREOF | SCHWECHTER, BRANDON ROSS | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18726900 | COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE COMPRISING GALACTO-OLIGOSACCHARIDE | LAU, JONATHAN S | 1693 | §102§103 | Non-Final OA | — | Pending | Jul 05, 2024 |
| 18712697 | NEW PEPTIDE AND USES THEREOF | SCHWECHTER, BRANDON ROSS | 1674 | §102§112 | Non-Final OA | — | Pending | May 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeo Cremar Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jonathan S Lau has the most, with 1 of Neo Cremar Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
